[{"data":1,"prerenderedAt":228},["ShallowReactive",2],{"drug-apixaban":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":45,"contraindications":104,"warnings":123,"renal":124,"monitoring":125,"interactions":126,"review":127,"examples":130,"atc":145,"iran":147,"links":163,"populations":180,"usApproval":223},"apixaban",1,{"fa":7,"en":8},"آپیکسابان","Apixaban","blood",{"fa":11,"en":12},"ضدانعقاد خوراکی (مهارکننده فاکتور Xa)","Oral anticoagulant (factor Xa inhibitor)",[14],{"name":15,"market":16},"Eliquis","US",[18,19,7,20,21],"eliquis","الیکوئیس","DOAC","NOAC",[23,37],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"tab-2-5","tablet","oral","2.5 mg tablet",{"amount":29,"unit":30,"perUnit":25,"scored":31},2.5,"mg",false,[16],[34],{"source":35,"section":36},"fda-eliquis","3",{"id":38,"form":25,"route":26,"label":39,"concentration":40,"markets":42,"refs":43},"tab-5","5 mg tablet",{"amount":41,"unit":30,"perUnit":25,"scored":31},5,[16],[44],{"source":35,"section":36},[46,72,94],{"id":47,"disease":48,"label":49,"population":52,"type":56,"unit":30,"dose":57,"refs":59,"notes":62},"af","atrial-fibrillation",{"fa":50,"en":51},"AF غیردریچه‌ای — ۵ mg دو بار در روز","Non-valvular AF — 5 mg twice daily",{"minAge":53},{"value":54,"unit":55},18,"year","fixed",{"perDose":41,"dosesPerDay":58},2,[60],{"source":35,"section":61},"2.1",[63],{"text":64,"refs":67},{"fa":65,"en":66},"اگر حداقل ۲ مورد از سن ≥۸۰، وزن ≤۶۰ kg، کراتینین ≥۱٫۵ وجود دارد: ۲٫۵ mg دو بار. با مهارکننده‌های قوی CYP3A4 و P-gp دوز نصف شود.","If at least 2 of age ≥80, weight ≤60 kg, creatinine ≥1.5: 2.5 mg twice daily. Halve with combined strong CYP3A4 + P-gp inhibitors.",[68,70],{"source":35,"section":69},"2",{"source":35,"section":71},"2.6",{"id":73,"disease":74,"label":75,"population":78,"type":56,"unit":30,"dose":80,"refs":82,"durationDays":84,"notes":86},"vte","venous-thromboembolism",{"fa":76,"en":77},"درمان DVT\u002FPE — ۱۰ mg دو بار ۷ روز، سپس ۵ mg دو بار","DVT\u002FPE treatment — 10 mg twice daily for 7 days, then 5 mg twice daily",{"minAge":79},{"value":54,"unit":55},{"perDose":81,"dosesPerDay":58},10,[83],{"source":35,"section":69},{"min":85,"max":85},7,[87],{"text":88,"refs":91},{"fa":89,"en":90},"پس از ۷ روز: ۵ mg دو بار. پیشگیری از عود پس از ۶ ماه: ۲٫۵ mg دو بار.","After 7 days: 5 mg twice daily. Recurrence prevention after 6 months: 2.5 mg twice daily.",[92,93],{"source":35,"section":69},{"source":35,"section":61},{"id":95,"disease":74,"label":96,"population":99,"type":56,"unit":30,"dose":101,"refs":102},"ortho",{"fa":97,"en":98},"پیشگیری DVT پس از تعویض لگن یا زانو — ۲٫۵ mg دو بار","DVT prophylaxis after hip\u002Fknee replacement — 2.5 mg twice daily",{"minAge":100},{"value":54,"unit":55},{"perDose":29,"dosesPerDay":58},[103],{"source":35,"section":69},[105,114],{"id":106,"severity":107,"text":108,"refs":111},"ci","block",{"fa":109,"en":110},"خونریزی پاتولوژیک فعال؛ حساسیت شدید.","Active pathological bleeding; severe hypersensitivity.",[112],{"source":35,"section":113},"4",{"id":115,"severity":116,"text":117,"refs":120},"boxed","warn",{"fa":118,"en":119},"هشدار جعبه‌ای: قطع زودهنگام خطر ترومبوز را بالا می‌برد؛ هماتوم نخاعی با بی‌حسی نخاعی.","Boxed warning: premature discontinuation raises thrombotic risk; spinal\u002Fepidural haematoma with neuraxial anaesthesia.",[121],{"source":35,"section":122},"Boxed Warning",[],[],[],[],{"status":128,"reviewer":129,"date":129},"unverified",null,[131,136,141],{"regimen":47,"formulation":38,"input":132,"expect":135},{"ageYears":133,"weightKg":134},70,75,{"perDose":41,"perDay":81},{"regimen":73,"formulation":38,"input":137,"expect":140},{"ageYears":138,"weightKg":139},50,80,{"perDose":81,"tabletsPerDoseRounded":58},{"regimen":95,"formulation":24,"input":142,"expect":144},{"ageYears":143,"weightKg":139},65,{"perDose":29},[146],"B01AF02",{"status":148,"forms":149,"refs":158},"registered",[150,154],{"code":151,"en":152,"fa":153},"51340","APIXABAN 5 MG TAB","قرص آپیکسابان ۵ میلی‌گرم",{"code":155,"en":156,"fa":157},"51339","APIXABAN 2.5 MG TAB","قرص آپیکسابان ۲٫۵ میلی‌گرم",[159],{"source":160,"section":161,"url":162},"darooyab-generic","G-5401\u002FApixaban","https:\u002F\u002Fwww.darooyab.ir\u002FG-5401\u002FApixaban",[164,168,172,175,178],{"kind":165,"url":166,"label":167},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=202155","NDA202155",{"kind":169,"url":170,"label":171},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae9b0","FDA Eliquis",{"kind":173,"url":174,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa613032.html",{"kind":176,"url":177,"label":146},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=B01AF02",{"kind":179,"url":162,"label":8},"darooyab",{"pregnancy":181,"lactation":190,"pediatric":199,"geriatric":207,"reproductive":215},{"level":182,"text":183,"quote":186,"refs":187},"caution",{"fa":184,"en":185},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data on ELIQUIS use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes.",[188],{"source":35,"section":189},"8.1",{"level":191,"text":192,"quote":195,"refs":196},"avoid",{"fa":193,"en":194},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because human exposure through milk is unknown, breastfeeding is not recommended during treatment with ELIQUIS.",[197],{"source":35,"section":198},"8.2",{"level":182,"text":200,"quote":203,"refs":204},{"fa":201,"en":202},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of ELIQUIS for the treatment of VTE and the reduction in the risk of recurrent VTE have been established in pediatric patients aged birth and older.",[205],{"source":35,"section":206},"8.4",{"level":182,"text":208,"quote":211,"refs":212},{"fa":209,"en":210},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total subjects in the ARISTOTLE and AVERROES clinical studies, >69% were 65 years of age and older, and >31% were 75 years of age and older.",[213],{"source":35,"section":214},"8.5",{"level":182,"text":216,"quote":219,"refs":220},{"fa":217,"en":218},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.",[221],{"source":35,"section":222},"8.3",{"kind":224,"refs":225,"id":167},"NDA",[226],{"source":35,"section":227},"SPL approval \u002F marketing category",1792191866033]